Evidence map›Paper›PMID 32965606›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2021

MAGEA10 expression is a predictive marker of early hepatic recurrence after curative gastrectomy for gastric and gastroesophageal junction cancer.

Keiichi Fujiya, Masanori Terashima, Keiichi Ohshima, Daisuke Aizawa, Takashi Sugino, Masakuni Serizawa, Kenichi Nakamura, Takeshi Nagashima, Keiichi Hatakeyama, Kenichi Urakami and 4 more

Open access · bronzeAbstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Research progress in effects of MAGE-A family on gastric cancer.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Keiichi FujiyaDivision of Gastric Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Masanori TerashimaDivision of Gastric Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. m.terashima@scchr.jp.ORCID http://orcid.org/0000-0002-2967-8267
Keiichi OhshimaMedical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Daisuke AizawaDivision of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Takashi SuginoDivision of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Masakuni SerizawaDrug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Kenichi NakamuraDivision of Gastric Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Takeshi NagashimaCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Keiichi HatakeyamaMedical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Kenichi UrakamiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Yasuto AkiyamaImmunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Yasuhiro TsubosaDivision of Esophageal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Ken YamaguchiShizuoka Cancer Center, Shizuoka, Japan.
Shizuoka Cancer Center · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResection for hepatic recurrence after gastrectomy in patients with gastric cancer may be curative; however, the prediction of hepatic recurrence remains intractable. Therefore, we aimed to explore predictive markers for hepatic recurrence in gastric and gastroesophageal junction cancer based on genetic information.

methodsThis study recruited 154 patients who underwent curative gastrectomy for pathological stage II or III primary gastric and gastroesophageal junction adenocarcinoma. Genes associated with hepatic recurrence were comprehensively analyzed using whole-exome sequencing and gene expression profiling (GEP), followed by immunohistochemistry analysis for MAGEA10. The cumulative incidences of hepatic recurrence, relapse-free survival, and overall survival were evaluated.

resultsA total of 12 patients with early hepatic recurrences were found within 2 years of surgery. Although there were no distinct gene mutations in recurrent patients, upregulation of MAGEA10 was identified in patients with early hepatic recurrence using GEP analysis. Immunostaining for MAGEA10 stained the cell nuclei in 29 (18.8%) of 154 samples. Furthermore, protein expression of MAGEA10 on immunohistochemistry was significantly related to a high MAGEA10 mRNA expression, high cumulative incidences of hepatic recurrence, and poor relapse-free survival. Overall survival did not differ significantly between positive and negative immunohistochemical staining for MAGEA10. The sensitivity and specificity of MAGEA10 staining for early hepatic recurrence were 58.3% and 84.5%, respectively.

conclusionsMAGEA10 represents a promising predictive marker for early hepatic recurrence after curative gastrectomy for gastric and gastroesophageal junction cancer.

Indexed as

GastrectomyAdenocarcinomaAgedAntigens, NeoplasmBiomarkers, TumorEsophageal NeoplasmsEsophagogastric JunctionFemaleGene Expression ProfilingHumansIncidenceLiverLiver NeoplasmsMaleNeoplasm ProteinsNeoplasm Recurrence, LocalAntigens, NeoplasmBiomarkers, TumorMAGEA10 protein, humanNeoplasm ProteinsComprehensive analysisGene expression profilingMAGEA family

Identifiers

PMID32965606
OpenAlexW3087886774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.